Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

Inclusion Criteria: * Histologically confirmed Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) (small lymphocytic lymphoma may be included) * Relapsed or refractory after at least one regimen and with no curative option with conventional therapy * Bidimensionally measurable disease (at least 2 cm) * No evidence of cerebral or meningeal involvement by lymphoma * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 * Signed informed consent form prior to enrollment * Women of childbearing potential and men must use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a women become pregnant or suspect she is pregnant while she or her partner is participating in this study, the patient should inform the treating physician immediately Exclusion Criteria: * Burkitt's lymphoma, lymphoblastic lymphoma, chronic lymphocytic leukemia and cutaneous T-cell lymphoma * Chemotherapy or radiation therapy or other investigational agents within 3 weeks prior to entering the study unless there is clear evidence of progression of disease and toxicity from previous treatment has resolved in which case study entry may be within 1 week of last treatment * Previous radioimmunotherapy within 12 weeks * Patients with known immunodeficiency virus (HIV) infection must not have cluster of differentiation (CD)4 cells \< 400/mm\^3 and who must not have a prior acquired immunodefici…